SCHEMBL29689474

SCHEMBL29689474

CN(CC(=O)c1ccccn1)C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
RAB9A P51151 1/20 0.44
CTNNB1 P35222 4/20 0.43
WNT3A P56704 3/20 0.43
GRM4 Q14833 1/20 0.43
ALDH1A1 P00352 2/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
LMNA P02545 1/20 0.40
NAPRT Q6XQN6 1/20 0.40
P4HTM Q9NXG6 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPK1 P28482 1/20 0.40
TNF P01375 1/20 0.39
KLF5 Q13887 1/20 0.39
NOD2 Q9HC29 1/20 0.39
NOD1 Q9Y239 1/20 0.39
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24443475 1.00 SMN1; SMN2 (0.44) SMN1; SMN2NPC1TP53RAB9ACTNNB1
SCHEMBL24443482 0.84 NPC1 (0.42) SMN1; SMN2NPC1TP53RAB9ACTNNB1
SCHEMBL29689910 0.84 NPC1 (0.42) SMN1; SMN2NPC1TP53RAB9ACTNNB1
SCHEMBL6284338 0.82 CTNNB1 (0.36) CTNNB1WNT3AALDH1A1HTR2CSLC6A4
SCHEMBL15549461 0.80 SMN1; SMN2 (0.39) SMN1; SMN2NPC1TP53RAB9ACTNNB1
SCHEMBL17831355 0.80 P2RX7 (0.43) RAB9AHTR2CSLC6A4
SCHEMBL29689871 0.80 P2RX7 (0.43) RAB9AHTR2CSLC6A4
SCHEMBL20524453 0.79 LMNA (0.52) SMN1; SMN2NPC1TP53RAB9ACTNNB1
SCHEMBL24443451 0.79 CCR1 (0.36) RAB9AGRM4LMNAHTR2CSLC6A4
SCHEMBL29689341 0.79 CCR1 (0.36) RAB9AGRM4LMNAHTR2CSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3601232-B1 COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES CURZA GLOBAL LLC (US) 2022-11-23 EP disclosed
US-20220274949-A1 COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES CURZA GLOBAL, LLC (US) 2022-09-01 US disclosed
US-11339140-B2 Compositions and methods comprising substituted 2-aminoimidazoles CURZA GLOBAL, LLC (US) 2022-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274949-A1 COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES AADAC, PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 SMN1; SMN2 3058/4885NPC1 2167/4885TP53 32/4885
US-11339140-B2 Compositions and methods comprising substituted 2-aminoimidazoles AADAC, PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 SMN1; SMN2 3058/4885NPC1 2167/4885TP53 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.